ReCode Therapeutics Administers Initial Dose in Phase 1b Study of RCT2100 for Cystic Fibrosis Treatment.

AstraZeneca’s Tagrisso (osimertinib) has received approval in the United States for treating adult patients with unresectable Stage III EGFRm NSCLC.

The FDA has granted IND approval for the world's first liquid recombinant Botulinum Toxin Type A formulation.

Innovent Reports NMPA NDA Approval for Picankibart (Anti-IL-23p19 Antibody) in Moderate to Severe Plaque Psoriasis Treatment.

Pfizer Voluntarily Removes All Batches of Sickle Cell Disease Drug OXBRYTA® (voxelotor) From Global Market.

Successful Phase III Trials for Genentech's Gazyva Indicate It Outperforms Standard Treatments in Lupus Nephritis Patients.

Kyowa Kirin Shares Initial Results from Rocatinlimab Phase 3 ROCKET HORIZON Study in Adults with Moderate to Severe Eczema.

UCB Unveils 4-Year BIMZELX® (bimekizumab-bkzx) Data for Moderate-to-Severe Plaque Psoriasis at EADV 2024.

Merck Updates Phase 3 KEYFORM-007 Trial on Experimental Fixed-Dose Favezelimab and Pembrolizumab Combo for PD-L1 Positive Metastatic Colorectal Cancer Post-Treatment.

Recent data reveal that Almirall’s EBGLYSS® (Lebrikizumab) maintained long-term disease control for up to three years in over 80% of adults and adolescents with moderate-to-severe atopic dermatitis.

Halia Therapeutics Unveils Encouraging Preclinical Obesity Results: HT-6184 with Semaglutide Boosts Weight Reduction and Maintains Lean Muscle.

These results indicate the effectiveness of troriluzole in changing the f-SARA score from baseline after three years of therapy.